MedTrace Logo

The Efficacy of Influenza Vaccine in Reducing Cardiovascular Events in Patients With Coronary Artery Diseases

NCT00607178 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2009-01-22

No results posted yet for this study

Summary

Influenza vaccine reduces the cardiovascular events in post-myocardial infarction (MI) patients and in those with stable angina (SA).

Conditions

Interventions

BIOLOGICAL

influenza vaccine

Intramuscular injection of one 0.5-mL dose of influenza vaccine

BIOLOGICAL

placebo for influenza vaccine

Intramuscular injection of one 0.5-mL dose of placebo for influenza vaccine

Sponsors & Collaborators

  • Shahid Beheshti University of Medical Sciences

    lead OTHER

Principal Investigators

  • Maryam Keshtkar-Jahromi, M.D.; M.P.H. · Infectious Diseases and Tropical Medicine Research Center, Shaheed Beheshti Medical University, Tehran, Iran

  • Hossein Vakili, M.D. · Cardiovascular Research Center, Shaheed Beheshti Medical University, Tehran, Iran

  • Ali Eskandari, MD · Shahid Beheshti University of Medical Sciences

  • Mohammad Rahnavardi, MD · Shahid Beheshti University of Medical Sciences

  • Sharareh Gholamin, MD · Shaheed Beheshti University (MC)

  • Seyed Mostafa Razavi, MD · Shaheed Beheshti University (MC)

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
25 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2008-09-30
Completion
2008-09-30

Countries

  • Iran

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00607178 on ClinicalTrials.gov